Medical technology company Implantica announces that the first commercial procedures using RefluxStop in the US have been successfully performed at the University of Southern California in Los Angeles.
The procedures were performed by surgeon John C. Lipham, who says that the patients are doing well. The implant treats acid reflux by restoring the body’s natural barrier against reflux.
“It was an honor to attend the procedures, which mark a historic milestone for the US market and Implantica, but above all for the many millions of American GERD patients,” says Peter Forsell, inventor of RefluxStop, founder and CEO of Implantica, in a comment.
He continues:
“It is very gratifying to see the strong interest in RefluxStop among US surgeons, gastroenterologists and patients. We will continue to build the launch in the US in a structured manner, clinic by clinic, with a focus on high-quality training for surgeons and the best possible treatment outcomes for patients. These patients with chronic symptoms finally have access to an effective surgical alternative with limited side effects, as confirmed by the 39 scientific papers on RefluxStop published to date. We are extremely pleased to be able to offer our new treatment to patients with a disease that affects 78 million Americans”.
